Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for post-stroke lower limb spasticity
2010-024579-23Phase 3Completed
- Sponsor
- Merz
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in poststroke spasticity (PSS) and spastic paresis (2 arms), sponsored by Merz. Primary endpoint: Change from baseline in Ashworth Scale Score for plantar flexors. Started Sep 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
poststroke spasticity (PSS)spastic paresis
Beyond the preview
Go deeper on 2010-024579-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024579-23.